• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cue Biopharma Inc (NQ: CUE )

    0.7524 -0.0076 (-1.00%)
    Streaming Delayed Price Updated: 9:48 AM EDT, Jul 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cue Biopharma Inc

    < Previous 1 2 Next >
    Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Investor Call
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.